Dianthus Therapeutics CFO Sells 8,224 Shares for $739,000

Dianthus Therapeutics' CFO, Ryan Savitz, sold 8,224 shares of the company's stock for approximately $739,000 on April 9, 2026, as reported in an SEC Form 4 filing. The transaction was structured as an option exercise and immediate sale under a Rule 10b5-1 plan, leaving Savitz with no direct ownership in the company's stock.

By Cory Renauer, The Motley Fool Sun, April 19, 2026 at 4:28 PM GMT+3 4 min read · Yahoo Finance · April 19, 2026, 13:28 UTC

Tickers: $DNTH

Topics: CFO activity executive stock sales SEC filings stock options

Read the full article at Yahoo Finance

More World news

Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC
Pelagos Insurance Reports Q3 2026 Earnings with Increased Gross Premiums Written Motley Fool · November 12, 2026, 18:11 UTC
Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC